<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8508183</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1289</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr. Neurol.</journal-id>
<journal-title-group>
<journal-title>Pediatric neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0887-8994</issn>
<issn pub-type="epub">1873-5150</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27267556</article-id>
<article-id pub-id-type="pmc">4921275</article-id>
<article-id pub-id-type="doi">10.1016/j.pediatrneurol.2016.03.015</article-id>
<article-id pub-id-type="manuscript">NIHMS774653</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations from the 2015 Strategic Planning Conference</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sahin</surname>
<given-names>Mustafa</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Henske</surname>
<given-names>Elizabeth P.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manning</surname>
<given-names>Brendan D.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ess</surname>
<given-names>Kevin C.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bissler</surname>
<given-names>John J.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klann</surname>
<given-names>Eric</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kwiatkowski</surname>
<given-names>David J.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roberds</surname>
<given-names>Steven L.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Silva</surname>
<given-names>Alcino J.</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hillaire-Clarke</surname>
<given-names>Coryse St.</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Young</surname>
<given-names>Lisa R.</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zervas</surname>
<given-names>Mark</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mamounas</surname>
<given-names>Laura A.</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<on-behalf-of>on behalf of the Tuberous Sclerosis Complex Working Group to Update the Research Plan</on-behalf-of>
</contrib-group>
<aff id="A1"><label>1</label>Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA</aff>
<aff id="A2"><label>2</label>Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA</aff>
<aff id="A3"><label>3</label>Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA</aff>
<aff id="A4"><label>4</label>Department of Pediatrics and Vanderbilt Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN 37232, USA</aff>
<aff id="A5"><label>5</label>University of Tennessee Health Science Center, Le Bonheur Children’s Hospital and St. Jude Children’s Research Hospital, Memphis, TN 38103, USA</aff>
<aff id="A6"><label>6</label>Center for Neural Science, New York University, New York, NY 10003, USA</aff>
<aff id="A7"><label>7</label>Tuberous Sclerosis Alliance, Silver Spring, MD 20910, USA</aff>
<aff id="A8"><label>8</label>Department of Neurobiology, Department of Psychiatry, Department of Psychology, Integrative Center for Learning and Memory, Brain Research Institute, University of California at Los Angeles, Los Angeles, CA 90095, USA</aff>
<aff id="A9"><label>9</label>National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA</aff>
<aff id="A10"><label>10</label>Division of Pulmonary Medicine, Department of Pediatrics and Division of Allergy, Pulmonary, and Critical Care, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232, USA</aff>
<aff id="A11"><label>11</label>Department of Neuroscience, Amgen Inc., Cambridge, MA 02142, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>To whom correspondence should be addressed. Tel: 617-919-6258; Fax: 617-730-0242; <email>mustafa.sahin@childrens.harvard.edu</email> (M.S.); Tel: 301-496-5745; Fax: 301-402-1501; <email>mamounas@ninds.nih.gov</email> (L.A.M.)</corresp>
<fn fn-type="conflict" id="FN3">
<p>
<bold>COMPETING INTERESTS</bold>
</p>
<p>M.S. has received research grants from Novartis. B.D.M. is on the scientific advisory boards for LAM Therapeutics and Navitor Pharmaceuticals, but these roles did not influence the content of this manuscript. M.S. is an Associate Editor for this journal but did not take part in the review and publication decisions.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>02</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2017</year>
</pub-date>
<volume>60</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<!--elocation-id from pubmed: 10.1016/j.pediatrneurol.2016.03.015-->
<abstract>
<p id="P1">On March 10–12, 2015, the National Institute of Neurological Disorders and Stroke and the Tuberous Sclerosis Alliance sponsored a workshop in Bethesda, Maryland to assess progress and new opportunities for research in tuberous sclerosis complex with the goal of updating the 2003 Research Plan for Tuberous Sclerosis (<ext-link ext-link-type="uri" xlink:href="http://www.ninds.nih.gov/about_ninds/plans/tscler_research_plan.htm">http://www.ninds.nih.gov/about_ninds/plans/tscler_research_plan.htm</ext-link>). In addition to the National Institute of Neurological Disorders and Stroke and Tuberous Sclerosis Alliance, participants in the strategic planning effort and workshop included representatives from six other Institutes of the National Institutes of Health, the Department of Defense Tuberous Sclerosis Complex Research Program and a broad cross-section of basic scientists and clinicians with expertise in tuberous sclerosis complex along with representatives from the pharmaceutical industry. This review summarizes outcomes from the extensive pre-meeting deliberations and final workshop recommendations, and includes: 1) progress in the field since publication of the initial 2003 research plan for tuberous sclerosis complex; 2) the key gaps, needs and challenges that hinder progress in tuberous sclerosis complex research; and 3) a new set of research priorities along with specific recommendations for addressing the major challenges in each priority area. The new research plan is organized around both short-term and long-term goals with the expectation that progress toward specific objectives can be achieved within a five- to ten-year timeframe.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>